Nuvalent, Inc. Class A (NUVL)

Nuvalent's stock has been impacted by several events over the past six months. The FDA accepted the NDA for zidesamtinib, following positive pivotal data from the ARROS-1 clinical trial. The stock price experienced fluctuations, hitting a 52-week high in January 2026. There has been significant insider selling activity. An earnings report missed expectations. Analysts have a consensus rating of "Moderate Buy" with a potential upside from its current price.

As a clinical-stage biopharmaceutical company, Nuvalent, Inc. is focused on the discovery and development of new therapies, rather than the commercial sale of approved products. Therefore, there is no information available regarding demand seasonality for its products or services, as its primary products are still in clinical trials and not yet on the market.

Nuvalent, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing targeted therapies for genetically defined cancers. Their research platform uses structure-guided drug design to create small molecule inhibitors. Key product candidates include NVL-520 (zidesamtinib), a selective RET inhibitor in Phase 2 trials for ROS1-positive NSCLC, NVL-655 (neladalkib), a covalent inhibitor targeting KRAS G12D mutations and a brain-penetrant ALK inhibitor in Phase 1/2 trials for ALK-positive NSCLC, and NVL-330, an investigational candidate for HER2-altered NSCLC. Nuvalent is also expanding its portfolio into other oncogenic targets.

Nuvalent, Inc. is headquartered in Cambridge, Massachusetts, and was founded in 2017. Its lead pipeline candidates, NVL-520 and NVL-655, are being evaluated in multicenter Phase 1/2 clinical trials across the United States and Europe.

Nuvalent's brand reputation is largely positive, particularly among analysts, with a consensus "Buy" rating. This is driven by the potential of its pipeline candidates, NVL-520 and NVL-655. Positive pivotal data and FDA acceptance have positively affected its reputation. However, challenges include potential risks related to safety profiles, trial outcomes, and regulatory decisions, as well as a missed earnings report.

Nuvalent, Inc. has 432 institutional owners and shareholders holding a total of 78,583,663 shares. Institutional shareholders own 99.60% of the stock, while Nuvalent insiders own 31.94%. Major institutional owners include Deerfield Management Company, L.P., Fmr Llc, and Paradigm Biocapital Advisors LP. The largest individual shareholder is James E. Flynn.